Moderator: Larry Gold Ph.D., Chairman & Co-Founder, Somalogic,
Panelists: Jun Wang Ph.D., CEO & Founder – iCarbonX, Simon Lovestone, Professor of Translational Neuroscience – University of Oxford, Iya Khalil, PhD, Chief Commercial Officer and Co-Founder, GNS Healthcare, Emanuel Petricoin III, Ph.D., University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, George Mason University
Medicine has always been “personalized” around phenotypic measures: The challenge has been the lack of ability to measure phenotype deeply enough to consistently provide meaningful and even actionable insights. To date, the genome has provided a limited prediction of phenotype, but it is increasingly clear that genomic analyses alone will never be more than an imprecise and partial approach to understanding real-time health and wellness. ”Molecular phenotype” measurements, in particular the constantly changing proteins that make up each individual, are absolutely needed if we will ever deliver precise – and personalized – medicine. This session will examine the connections between genotype and phenotype, and their respective roles in the emerging deep insights into human health and disease.